Allianz Asset Management
RAPT

Allianz Asset Management’s RAPT Therapeutics RAPT Stock Holding History

Allianz Asset Management’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,263
Closed -$301K – 2220
2023
Q3 		$301K Buy
+2,263
New +$369K ﹤0.01% 2062

Other funds holding RAPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Allianz Asset Management's RAPT Position: Q4 2023 in Review

Allianz Asset Management sold out of RAPT Therapeutics (RAPT) in Q4 2023, closing a stake of 2,263 shares — an estimated $301K sold.

Allianz Asset Management first reported a position in RAPT in Q3 2023 and held it in 1 quarter. The position peaked at $301K in Q3 2023. 108 funds tracked by Wall St. Rank hold RAPT as of Q4 2023.

  • Allianz Asset Management reported no remaining RAPT Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Allianz Asset Management sold 2,263 RAPT Therapeutics shares in Q4 2023, an estimated $301K.
  • Allianz Asset Management first reported a position in RAPT Therapeutics in Q3 2023 and held it in 1 quarter.
  • Allianz Asset Management's RAPT Therapeutics position peaked at $301K in Q3 2023.
  • 108 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q4 2023.

Based on Allianz Asset Management's 13F filing for Q4 2023, filed 12 Feb 2024.